id: nalmefene_availability_to_heavy_drinking_reduction
name: Nalmefene Availability and Access â†’ Reduction in Heavy Drinking Episodes
from_node:
  node_id: nalmefene_availability
  node_name: Nalmefene Availability and Access
to_node:
  node_id: heavy_drinking_reduction
  node_name: Reduction in Heavy Drinking Episodes
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Nalmefene acts as an opioid antagonist similar to naltrexone, blocking
  endogenous opioid reward pathways'
- 'Step 2: Opioid receptor blockade reduces the pleasurable and reinforcing effects
  of alcohol consumption'
- 'Step 3: Diminished reinforcement leads to decreased motivation for heavy drinking
  episodes'
- 'Step 4: Consistent medication availability and use results in reduced frequency
  and intensity of heavy drinking'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: 'Henry R Kranzler and Emily E Hartwell 2023. "Medications for
    treating alcohol use disorder: A narrative review.." *Alcohol, clinical & experimental
    research*. https://doi.org/10.1111/acer.15118'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.670422'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
